BioNTech Seeks Shareholder Approval to Fund Strategic Oncology Pivot

BioNTech asks shareholders for authority to raise capital, supported by a €17B cash reserve, as it navigates revenue decline and a strategic pivot to oncology ahead of its founders' departure.

As BioNTech prepares for a significant strategic realignment, its management is asking shareholders for enhanced financial authority. The company is navigating this transition—marked by the impending departure of its founders and declining revenues—with the support of a substantial multi-billion euro cash reserve intended to fund its costly shift toward oncology.

Shareholder Vote to Grant Capital Raising Flexibility

A key item on the agenda for the virtual Annual General Meeting on May 15 is a proposal to establish what the company terms the "Authorized Capital 2026." This measure would empower the board to increase the company's share capital by up to 50 percent without needing to seek shareholder approval for each individual action. Management frames this requested flexibility as a strategic tool, enabling BioNTech to swiftly raise equity capital for potential acquisitions or licensing deals as opportunities arise in its refocused therapeutic areas.

The rationale behind securing such financial maneuvering room becomes clear when examining recent performance. The Mainz-based firm reported a net loss of €1.14 billion for 2025. Looking ahead to 2026, BioNTech anticipates a revenue decline of approximately 25 percent, projecting sales between €2.0 and €2.3 billion. These figures contrast with persistently high expenditures, including a research and development budget for the current year that could reach €2.5 billion.

This deliberate period of financial contraction is cushioned by a formidable liquidity position. The company closed 2025 with cash and equivalents totaling €17.2 billion. Furthermore, the retained earnings of about €6.9 billion are slated to be transferred entirely to operational reserves, with no dividend distribution planned under the current circumstances.

Governance and Structural Shifts to Support Oncology Focus

To structurally reinforce its commitment to cancer research, BioNTech is proposing an expansion of its Supervisory Board from six to eight members. The two additional seats are designated for experts specializing in oncology and clinical development. Concurrently, the company plans to implement a domination and profit transfer agreement with its subsidiary, BioNTech Discovery GmbH. This move is designed to streamline decision-making processes and consolidate cash flows, while also triggering direct changes to the group's tax arrangements.

These governance changes run parallel to the ongoing search for successors to founders Ugur Sahin and Özlem Türeci, who are scheduled to depart the company by the end of 2026. The company asserts that its clinical pipeline will remain operationally unaffected by this leadership transition. BioNTech expects to have 15 ongoing Phase 3 trials in oncology by year-end, with pivotal data readouts from late-stage studies across various cancer types anticipated during the course of 2026.